Physician profile
Milagros Huerta
NPI 1730121229
$25,321.49
in general payments reported to CMS, 2019-2025
8 companies · $9,292 in 2025
The $9,292 reported for 2025 was more than what 88% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,924 · 2020: $158 · 2021: $81.98 · 2022: $5,138 · 2023: $5,256 · 2024: $471 · 2025: $9,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,414 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,208 · Travel and Lodging: $2,399 · Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,413.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,208.00 |
| Travel and Lodging | $2,399.16 |
| Food and Beverage | $998.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $12,259.64 | 2019-2025 | Sogroya, Norditropin |
| Ascendis Pharma Endocrinology INC | $8,216.43 | 2022-2025 | Skytrofa |
| Ferring Pharmaceuticals INC. | $3,465.25 | 2019 | |
| Novo Nordisk As | $1,025.38 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $137.10 | 2024 | Imcivree |
| Endo Pharmaceuticals INC. | $125.73 | 2019 | |
| Abbvie INC. | $91.96 | 2019-2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milagros Huerta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.